» Articles » PMID: 34316007

Harnessing Murine Models of Crohn's Disease Ileitis to Advance Concepts of Pathophysiology and Treatment

Overview
Journal Mucosal Immunol
Publisher Elsevier
Date 2021 Jul 28
PMID 34316007
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Crohn's disease (CD) and ulcerative colitis (UC) are both characterized by chronic inflammation and severe dysfunction of the gastrointestinal tract. These two forms of inflammatory bowel disease (IBD) represent distinct clinical disorders with diverse driving mechanisms; however, this divergence is not reflected in currently approved therapeutics that commonly target general proinflammatory pathways. A compelling need therefore remains to understand factors that differentiate the topology and the distinct clinical manifestations of CD versus UC, in order to develop more effective and specialized therapies. Animal models provide valuable platforms for studying IBD heterogeneity and deciphering disease-specific mechanisms. Both the established and the newly developed ileitis mouse models are characterized by various disease initiating mechanisms and diverse phenotypic outcomes that reflect the complexity of human CD-ileitis. Microbial dysbiosis, destruction of epithelial barrier integrity, immune cell deregulation, as well as the recently described genome instability and stromal cell activation have all been proposed as the triggering factors for the development of ileitis-associated pathology. In this review, we aim to critically evaluate the mechanistic underpinnings of murine models of CD-ileitis, discuss their phenotypic similarities to human disease, and envisage their further exploitation for the development of novel targeted and personalized therapeutics.

Citing Articles

Oral Delivery of miR146a Conjugated to Cerium Oxide Nanoparticles Improves an Established T Cell-Mediated Experimental Colitis in Mice.

Apte A, Dey P, Julakanti S, Midura-Kiela M, Skopp S, Canchis J Pharmaceutics. 2025; 16(12.

PMID: 39771552 PMC: 11679827. DOI: 10.3390/pharmaceutics16121573.


The emerging role of oxidative stress in inflammatory bowel disease.

Muro P, Zhang L, Li S, Zhao Z, Jin T, Mao F Front Endocrinol (Lausanne). 2024; 15:1390351.

PMID: 39076514 PMC: 11284038. DOI: 10.3389/fendo.2024.1390351.


Crohn's disease and clinical management today: How it does?.

da Silva Junior R, Apolonio J, de Souza Nascimento J, da Costa B, Malheiro L, Silva Luz M World J Methodol. 2024; 13(5):399-413.

PMID: 38229938 PMC: 10789097. DOI: 10.5662/wjm.v13.i5.399.


The landscape of immune dysregulation in Crohn's disease revealed through single-cell transcriptomic profiling in the ileum and colon.

Kong L, Pokatayev V, Lefkovith A, Carter G, Creasey E, Krishna C Immunity. 2023; 56(2):444-458.e5.

PMID: 36720220 PMC: 9957882. DOI: 10.1016/j.immuni.2023.01.002.


Ileitis-associated tertiary lymphoid organs arise at lymphatic valves and impede mesenteric lymph flow in response to tumor necrosis factor.

Czepielewski R, Erlich E, Onufer E, Young S, Saunders B, Han Y Immunity. 2021; 54(12):2795-2811.e9.

PMID: 34788601 PMC: 8678349. DOI: 10.1016/j.immuni.2021.10.003.

References
1.
Lamb C, Kennedy N, Raine T, Hendy P, Smith P, Limdi J . British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019; 68(Suppl 3):s1-s106. PMC: 6872448. DOI: 10.1136/gutjnl-2019-318484. View

2.
Odze R . Diagnostic problems and advances in inflammatory bowel disease. Mod Pathol. 2003; 16(4):347-58. DOI: 10.1097/01.MP.0000064746.82024.D1. View

3.
Hendrickson B, Gokhale R, Cho J . Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002; 15(1):79-94. PMC: 118061. DOI: 10.1128/CMR.15.1.79-94.2002. View

4.
Neurath M . Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017; 14(5):269-278. DOI: 10.1038/nrgastro.2016.208. View

5.
Gisbert J, Chaparro M . Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. J Crohns Colitis. 2019; 14(5):694-709. DOI: 10.1093/ecco-jcc/jjz195. View